Shares of biotech firm Nektar Therapeutics collapsed after the company revealed in an earnings call that there had been manufacturing issues in two batches of ...
View full coverage on Google NewsNektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues - Barron's
Read More
Bagikan Berita Ini
Related Posts :
The OPEC Deal Was The First Step To $100 Oil - OilPrice.com- The No. 1 job of 2019 pays $140,000 — and its hiring growth has exploded 74% - MarketWatch
- Peloton plunges after investor says the stock is worth only $5 - CNN
- Colombia threatens to sue Walmart for linking the country to cocaine for a Christmas sweater - The Washington Post
- Testing tech ideas in public? San Francisco says get permit - The Associated Press
0 Response to "Nektar Therapeutics Stock Plunges on Earnings, Disclosure of Drug Trial Issues - Barron's"
Post a Comment